Early onset of hyperkalemia in patients treated with low molecular weight heparin: A prospective study

Pharmacoepidemiology and Drug Safety

Volumn 13, Issue 5, 2004, Pages 299-302

  Koren Michowitz, Maya ^a   Avni, Batia ^a   Michowitz, Yoav ^a   Moravski, Gil ^a   Efrati, Shai ^a   Golik, Ahuva ^a  

^a ASSAF HAROFEH MEDICAL CENTER   (Israel)

Author keywords

Aldosterone; Hyperkalemia; Low molecular weight heparin (LMWH); Medications

Indexed keywords

ALANINE AMINOTRANSFERASE; ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ASPARTATE AMINOTRANSFERASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BICARBONATE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; POTASSIUM; SODIUM; UREA;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; FEMALE; HEART ATRIUM FIBRILLATION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERKALEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PH; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; VENOUS THROMBOEMBOLISM;

ALDOSTERONE; ANTICOAGULANTS; CREATININE; ENOXAPARIN; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; HYPERKALEMIA; MALE; MIDDLE AGED; PLATELET COUNT; PROSPECTIVE STUDIES; SODIUM; UREA;

EID: 2542554966     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.881     Document Type: Article

References (11)

1. Oster JR, Singer I, Fishman LM. Heparin-induced aldosterone suppression and hyperkalemia. Am J Med 1995; 98: 575-586.
2. Monreal M, Lafoz E, Salvador R, Ronacales J, Navarro A. Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalemia. Eur J Clin Pharmacol 1989; 37: 415-418.
3. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1-17.
4. Levesque H, Verdier S, Cailleux N, et al. Low molecular weight heparins and hypoaldosteronism. Br Med J 1990; 300: 1437-1438.
5. Canova CR, Fischler MP, Reinhart WH. Effect of low molecular weight heparin on serum potassium. Lancet 1997; 349: 1447-1448.
6. Siebles M, Andrassy K, Vecsei P, et al. Dose dependent suppression of mineralocorticoid metabolism by different heparin fractions. Thromb Res 1992; 66: 467-473.
7. Cailleux N, Moore N, Levesque H, Courtois H, Godin M. A low molecular weight heparin decreases plasma aldosterone in patients with primary hyperaldosteronism. Eur J Clin Pharmacol 1992; 43: 185-187.
8. Marcelli JM, Lalau JD, Abourachid H, et al. Unlike heparin, low-molecular weight heparin does not suppress aldosterone production. Horm Metab Res 1989; 21: 402.
9. Gonzalez-Martin G, Diaz-Molinas MS, Martinez AM, Ortiz M. Heparin induced hyperkalemia: a prospective study. Int J Clin Pharmacol Ther Toxicol 1991; 29: 446-450.
10. Edes TE, Sunderrajan EV. Heparin induced hyperkalemia. Arch Intern Med 1985; 145: 1070-1072.
11. Busch EH, Ventura HO, Lavie CJ. Heparin induced hyperkalemia. South Med J 1987; 80: 1450-1451.